Navigation Links
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
Date:10/26/2008

- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs -

NEW HAVEN, Conn., Oct. 26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery, development and commercialization of novel antibiotics for the treatment of antibiotic-resistant infections, today announced positive results from a Phase 2 clinical trial with the oral form of its compound, radezolid (RX-1741), for the treatment of uncomplicated skin and skin structure infections (uSSSI). These results were announced at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th annual meeting (2008 ICAAC/IDSA Joint Meeting) held October 25 - 28 in Washington, D.C.

The open-label trial met both its primary (efficacy) and secondary (safety) endpoints. All doses of radezolid were as efficacious as linezolid (Zyvox(R), currently marketed by Pfizer) and demonstrated a good safety profile. The study also showed that radezolid was approximately four times more potent than linezolid against bacteria cultured from subjects in the study, including against methicillin-resistant Staphylococcus aureus (MRSA), with MIC90s of 0.5mg/L and 2.0mg/L respectively. MIC90s for other relevant bacterial isolates in the study were 0.5mg/L and 2.0mg/L for MRSA and 0.25mg/L and 1.0ug/ml for Streptococcus pyogenes for radezolid and linezolid, respectively. MIC90 is defined as the minimum inhibitory concentration necessary to inhibit the growth of 90 percent of the bacteria.

"We are pleased to report that our novel oxazolidinone, radezolid, may provide a safe and more potent alternative to the only currently marketed drug in this antibiotic class," said Susan Froshauer, PhD, President and CEO of Rib-X Pharmaceuticals. "In particular, radezolid offers a broader spectrum that includes atypicals an
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
2. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
3. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
4. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... N.C. , Aug. 29, 2014 The ... of regulatory and marketplace changes. CI leaders who adjust ... In a new Best Practices, LLC study ... of actionable insights, including: - Use secondary ... than primary research - Internal staff who ...
(Date:8/29/2014)... , Aug. 29, 2014 Pomerantz LLP has ... or the "Company") (NASDAQ: EDAP ) and ... United States District Court, Southern District of ... on behalf of a class consisting of all persons ... 2013 and July 30, 2014, inclusive (the "Class Period"). This ...
(Date:8/29/2014)...   Mast Therapeutics, Inc. (NYSE MKT: ... Santosh Vetticaden, Chief Medical Officer and Senior Vice ... reasons, in mid-September.  Edwin L. Parsley , ... which Mast acquired earlier this year, will assume ... Chief Medical Officer.  Dr. Parsley previously was with ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4
... Calif., April 8, 2011 Amgen (NASDAQ: ... the expansion of its operations in Brazil, including the ... has also agreed to reacquire rights in Brazil to ... acquired by Hypermarcas). Together, these transactions will provide Amgen ...
... the leading health care supply contracting company, announced today ... to its portfolio of agreements for Cardiac Rhythm Management ... leading provider of medical devices which treat cardiac, neurological ... portfolio of arrhythmia management products, including pacemakers, implantable cardioverter ...
Cached Medicine Technology:Amgen Establishes Commercial Operations in Brazil 2Amgen Establishes Commercial Operations in Brazil 3Amgen Establishes Commercial Operations in Brazil 4Novation Announces the Addition of St. Jude Medical to the Cardiac Rhythm Management Products Portfolio 2
(Date:8/31/2014)... CA (PRWEB) August 31, 2014 Kicking ... kicking coach Matt Nelson of Matt Nelson Kicking Academy ... business, and on being a National Camp Series (NCS) ... of HustedKicking.com. , "Matt Nelson is another high quality ... many attributes to coaching. He is an outstanding ...
(Date:8/31/2014)... August 31, 2014 This September, ... California State Library, celebrates 30 years of changing ... Since its inception, California’s Library Literacy Services has ... learn to read and write. , To mark ... the state is launching a month-long awareness campaign ...
(Date:8/31/2014)... 2014 With the NCAA set to ... hosted an interview with Yale University Associate Athletic Director ... Yale’s approach to ensuring student-athlete experience that is consistent ... highlighted a number of key factors that contribute to ... critical factor in creating this culture seems simple at ...
(Date:8/31/2014)... 31 August 2014: Renal denervation seems to be more ... hypertension when it includes accessory renal arteries, according to ... Schmiedel from Germany. , Dr Schmiedel said: "More than ... is defined as blood pressure (BP) greater than 140/90 ... hypertension (rHTN) and are unable to reduce BP below ...
(Date:8/31/2014)... Barcelona, Spain Sunday 31 August 2014: Drinking tea ... 131 000 people presented at ESC Congress today by ... "If you have to choose between tea or coffee ... are important components of our way of life. Their ... the past with sometimes divergent results. We investigated the ...
Breaking Medicine News(10 mins):Health News:MichaelHusted.com Features an Interview with Matt Nelson of Matt Nelson Kicking Academy on His Role as a Kicking Coach and on Becoming a National Camp Series Associate 2Health News:MichaelHusted.com Features an Interview with Matt Nelson of Matt Nelson Kicking Academy on His Role as a Kicking Coach and on Becoming a National Camp Series Associate 3Health News:California Library Literacy Services Celebrates 30th Anniversary 2Health News:California Library Literacy Services Celebrates 30th Anniversary 3Health News:Yale University’s Steve Conn Discusses NCAA Football, Student-Athlete Experience, & Social Media SCI Talk Interview 2Health News:Yale University’s Steve Conn Discusses NCAA Football, Student-Athlete Experience, & Social Media SCI Talk Interview 3Health News:Renal denervation more successful when it includes accessory arteries 2Health News:Drinking tea reduces non-CV mortality by 24 percent 2Health News:Drinking tea reduces non-CV mortality by 24 percent 3
... ARLINGTON, Va., Nov. 16 Acknowledging that their results ... in the International Journal of Andrology nevertheless attempt to link ... to maternal exposure to phthalates. The researchers, led by ... previous, and much publicized, study of phthalate exposure to evaluate ...
... , SOUTH SAN FRANCISCO, Calif., Nov. 15 ... Company will hold a teleconference and webcast at 8:00 a.m. Eastern ... Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of ... Conference Call and Webcast Information , To participate ...
... 15 The World Champion New York Yankees ... at New York Blood Center,s (NYBC) Biennial Chairman,s Dinner this ... The event is chaired by William J. Mullaney, MetLife ... the opportunity to honor these two outstanding supporting organizations as ...
... ... its intention to begin the drug registration process in Brazil and Colombia for its ... United States for the treatment of moderate to severe (Stage 2) chronic pain. ... Plantation, FL (Vocus) ...
... , ... from the RecordAF,registry (REgistry on Cardiac rhythm disORDers assessing ... Sessions of the,American Heart Association, show that in recently ... rhythm-control strategy,provides better short term control of the arrhythmia ...
... when new lead is needed in heart devices, ... -- Replacing or adding wiring increases the risk ... replace a pacemaker or other heart rhythm-stabilizing device, ... complication rates among patients enrolled in the REPLACE ...
Cached Medicine News:Health News:Swan Study Authors Note Results 'Not Straightforward' 2Health News:Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer 2Health News:World Champion New York Yankees, BNY Mellon to be Honored as New York Blood Center 'Champions of Life' 2Health News:Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever 2Health News:Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever 3Health News:Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever 4Health News:First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm-Control Strategy With Current Therapies Achieves Improved Disease Control but not Clinical Outcomes 2Health News:First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm-Control Strategy With Current Therapies Achieves Improved Disease Control but not Clinical Outcomes 3Health News:First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm-Control Strategy With Current Therapies Achieves Improved Disease Control but not Clinical Outcomes 4Health News:First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm-Control Strategy With Current Therapies Achieves Improved Disease Control but not Clinical Outcomes 5
Comfor™ Cast Boot - Rocker Sole - Closed Toe...
The Multi-Purpose Medical-Surgical Shoe...
... assay for the qualitative and ... to Gliadin in human serum. ... be used as an aid ... disorders, mainly Coeliac Disease. This ...
... For use as a non-reactive quality assurance reagent ... Toxoplasma gondii (TOXO IgG and TOXO IgM), IgG ... and rubella IgM), IgG and IgM antibodies to ... IgM antibodies to herpes simplex virus types 1 ...
Medicine Products: